Clinical trials: Mild Cognitive Impairment
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
- Trial name
- CONCORDE (NCT03448445)
- Testing
- Usual care setting
- Where
- 16 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Alzheimer's Disease
Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better.
- Trial name
- NCT00876863
- Testing
- CERE-110: Adeno-Associated Virus injection Surgery
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Sangamo Therapeutics
Cognitive Impairment, Mild
Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations on a wearable device enhanced with biosensors.
- Trial name
- TCIFCF (NCT04972019)
- Testing
- Telerehabilitation Experimental Group
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bright Cloud International Corp
Mild Cognitive Impairment, Adults
Comparative Effects of a2 Skim Milk on Mild Cognitive Impairment in Older Adults
The aim of the study is to compare the effects of powdered skim milk containing A2 β-casein only versus conventional powdered skim milk containing A1 and A2 β-casein milk on cognition, inflammation, and dietary intake in adults…
- Trial name
- NCT05741047
- Testing
- a2Milk skim milk powder, Yili skim milk powder
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- a2 Milk Company Ltd.
Mild Cognitive Impairment Due to Alzheimer's Disease
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an…
- Trial name
- NCT02284906
- Testing
- Pioglitazone
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 40 people
- Sponsor
- Takeda
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Trial name
- EARS (NCT04928690)
- Volunteers
- 140 people
- Sponsor
- Novoic Limited
Alzheimer's Disease
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test…
- Trial name
- NCT01561430
- Testing
- LY2886721
- Where
- 34 sites in United States, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment
Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
- Trial name
- NCT02211560
- Testing
- Phosphatidylserine
- Where
- 15 sites in United States, Israel
- Volunteers
- 97 people
- Sponsor
- Enzymotec
Alzheimer Disease, Mild Cognitive Impairment
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- REPHRASE (NCT05107882)
- Where
- 7 sites in United States, Canada
- Volunteers
- 466 people, healthy volunteers welcome
- Sponsor
- Optina Diagnostics Inc.
Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI)
Evaluation of SCALE PET Software for Quantitative Brain PET Analysis in Alzheimer's Disease
The goal of this study is to learn if medical image analysis software, Neurophet SCALE PET, can enhance readers' amyloid beta positivity performance in people with Alzheimer's Disease.
- Trial name
- NCT07417540
- Testing
- Neurophet SCALE PET
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- NEUROPHET
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios
Alzheimers Disease
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
- Trial name
- TRAVELLER (NCT07177352)
- Testing
- No Intervention
- Where
- 234 sites in United States, Argentina and 13 more
- Volunteers
- 80,000 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Parkinson's Disease, PD
iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS
The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for…
- Conditions
- Parkinson's Disease, PD, Mild Cognitive Impairment, MCI
- Trial name
- iPACES-PD (NCT05810454)
- Testing
- iPACES (interactive Physical and Cognitive Exercise System), PACE (Physical and Cognitive Exercise)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- iPACES LLC
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx
Cognitive Decline, Cognitive Impairment, Mild
Efficacy of a Mobile-based Multidomain Intervention to Improve Cognitive Function and Health-related Outcomes Among Older Korean Adults With a High Risk of Dementia
This study investigated the efficacy of the Silvia program, a mobile-based multidomain intervention, to improve cognitive function and health-related outcomes of older adults with a high risk of dementia.
- Conditions
- Cognitive Decline, Cognitive Impairment, Mild, Aging, Dementia
- Trial name
- NCT05675137
- Testing
- mobile-based, paper-based
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Silvia Health
Mild Cognitive Impairment, So Stated
Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
- Trial name
- NCT00422981
- Testing
- AL-108
- Where
- 17 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Allon Therapeutics
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS